Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,504,310 | 3,225,560 | 2,699,230 | 2,567,430 | 2,729,030 |
| Marketable Securities | 3,122,910 | 1,966,170 | 2,533,350 | 2,199,210 | 3,057,390 |
| Receivables | 4,142,620 | 4,638,260 | N/A | 4,180,700 | -36,250 |
| Inventories | 2,777,320 | 2,761,220 | 2,647,170 | 2,543,980 | 1,289,050 |
| Other current assets | 4,059,320 | 3,783,170 | 7,890,690 | 3,473,600 | 9,204,020 |
| TOTAL | $17,606,480 | $16,374,380 | $15,770,440 | $14,964,920 | $16,243,240 |
| Non-Current Assets | |||||
| Investments And Advances | 2,150,650 | 2,170,560 | 2,028,100 | 2,249,830 | 2,371,050 |
| Other Non-Current Assets | 21,921,270 | 21,791,030 | 20,207,190 | 20,046,990 | 20,607,450 |
| TOTAL | $24,071,920 | $23,961,590 | $22,235,290 | $22,296,820 | $22,978,500 |
| Total Assets | $47,862,740 | $46,539,840 | $44,223,470 | $43,349,380 | $45,428,280 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 0 | N/A | N/A | N/A | 3,065,910 |
| Accounts payable and accrued liabilities | 2,634,710 | 1,336,370 | 0 | 1,243,280 | 0 |
| Accrued Expenses | 1,767,670 | 430,310 | N/A | 512,920 | 2,161,070 |
| Other current liabilities | 1,628,330 | 3,744,430 | 4,132,960 | 3,908,980 | 2,719,190 |
| TOTAL | $7,424,940 | $7,045,310 | $6,201,160 | $9,080,460 | $9,546,980 |
| Non-Current Liabilities | |||||
| Long Term Debt | 6,535,920 | 6,644,540 | 6,861,680 | 3,766,860 | 3,827,690 |
| Other Non-Current Liabilities | 2,909,510 | 2,804,670 | 2,453,610 | 2,355,149 | 1,699,430 |
| TOTAL | $13,535,120 | $13,388,850 | $12,988,060 | $9,891,439 | $9,568,580 |
| Total Liabilities | $20,960,100 | $20,434,160 | $19,189,240 | $18,971,900 | $19,115,580 |
| Shareholders' Equity | |||||
| Common Shares | 768,840 | 781,550 | 806,970 | 794,260 | 806,970 |
| Retained earnings | 27,141,660 | 27,684,790 | 29,244,690 | 28,382,280 | 28,626,750 |
| Other shareholders' equity | -1,477,370 | -2,844,040 | -5,531,680 | -5,304,620 | -3,741,430 |
| TOTAL | $26,902,640 | $26,105,670 | $25,034,210 | $24,377,480 | $26,312,690 |
| Total Liabilities And Equity | $47,862,740 | $46,539,830 | $44,223,450 | $43,349,380 | $45,428,270 |